Volume 23, No 3, Mar 2013

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 23 Issue 3, March 2013: 326-328

RESEARCH HIGHLIGHTS

A new horizon for epigenetic medicine?

Shuzhen Chen¹ and Yang Shi¹

¹Division of Newborn Medicine and Program in Epigenetics, Department of Medicine, Boston Children's Hospital and Department of Cell Biology, Harvard Medical School, Boston MA, 02115, USA Correspondence: Yang Shi,(yshi@hms.harvard.edu)

Histone lysine demethylases are chromatin modifiers that play important roles in many pathological processes such as inflammation and cancer, making them potentially attractive drug targets. In a recent study, Kruidenier et al. provided proof of concept by identifying chemical matters that inhibit demethylation mediated by the two related histone H3 lysine 27 demethylases, KDM6A and 6B (UTX and JMJD3). The KDM6 inhibitor shows remarkable substrate selectivity and can inhibit transcription of a plethora of pro-inflammatory genes in cell culture by altering H3K27me3 level at some of the KDM6 target genes.

Cell Research (2013) 23:326–328; doi:10.1038/cr.2012.136; published online 18 September 2012

FULL TEXT | PDF

Browse 2285